NCT03200496View on ClinicalTrials.gov

Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2017

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions

Healthy

Interventions

DRUG

DA-5206(Fasting)

Test drug l : DA-5206(Fasting)

DRUG

DA-5206(Fed)

Test drug ll : DA-5206(Fed)

DRUG

TALION®

Reference drug : Talion®

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT03200496 - Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects | Biotech Hunter | Biotech Hunter